Jean-francois Spinella

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

TP53-mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition.

TP53-mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition.

Journal: Science advances
Published: May 15, 2026

High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort.

High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort.

Journal: Biomarker research
Published: May 15, 2025

CD33 epitope editing unlocks UM171-expanded cord blood grafts for AML immunotherapy.

CD33 epitope editing unlocks UM171-expanded cord blood grafts for AML immunotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: April 24, 2025

IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia.

IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia.

Journal: Biomarker research
Published: November 06, 2024

DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition.

DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition.

Journal: EMBO reports
Published: October 09, 2024

SF3B1 mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemia.

SF3B1 mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemia.

Journal: Science advances
Published: March 22, 2024

Immunotherapeutic targeting of surfaceome heterogeneity in AML.

Immunotherapeutic targeting of surfaceome heterogeneity in AML.

Journal: Cell reports
Published: October 05, 2023

Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML.

Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML.

Journal: Blood advances
Published: September 21, 2023

DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML.

DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML.

Journal: Leukemia
Published: May 29, 2023

HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition.

HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition.

Journal: Blood advances
Published: July 26, 2021

UM171 Preserves Epigenetic Marks that Are Reduced in Ex Vivo Culture of Human HSCs via Potentiation of the CLR3-KBTBD4 Complex.

UM171 Preserves Epigenetic Marks that Are Reduced in Ex Vivo Culture of Human HSCs via Potentiation of the CLR3-KBTBD4 Complex.

Journal: Cell stem cell
Published: July 21, 2020

Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia.

Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia.

Journal: Nature communications
Published: January 20, 2020
Showing 1-12 of 30

Last Updated: 09/26/2026